Article Details
Retrieved on: 2022-06-04 20:00:31
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer (PFE) Ibrance (palbociclib) failed to meet statistical significance for overall survival in a phase 3 trial as a combination treatment for ...
Article found on: seekingalpha.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here